{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T10:26:33Z","timestamp":1749637593549},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/jcp.0b013e3181befa2a","type":"journal-article","created":{"date-parts":[[2009,11,7]],"date-time":"2009-11-07T08:15:39Z","timestamp":1257581739000},"page":"542-547","source":"Crossref","is-referenced-by-count":13,"title":["Onset and Persistence of Antipsychotic Response in Patients With Schizophrenia"],"prefix":"10.1097","volume":"29","author":[{"given":"Ira D.","family":"Glick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A.","family":"Bossie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla M.","family":"Canuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1176\/appi.ps.57.1.139","article-title":"Interpreting the results of the CATIE study.","volume":"57","author":"Lieberman","year":"2006","journal-title":"Psychiatr Serv"},{"key":"R3-5-20210128","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.","volume":"60","author":"Agid","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","article-title":"Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.","volume":"57","author":"Leucht","year":"2005","journal-title":"Biol Psychiatry"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1176\/ajp.2006.163.4.743","article-title":"Time course for antipsychotic treatment response in first-episode schizophrenia.","volume":"163","author":"Emsley","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00005053-199602000-00009","article-title":"Prediction of positive placebo response among chronic schizophrenic outpatients.","volume":"184","author":"Taiminen","year":"1996","journal-title":"J Nerv Ment Dis"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia.","volume":"41","author":"McEvoy","year":"2007","journal-title":"J Psychiatr Res"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.","volume":"54","author":"Small","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \"Seroquel\" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry"},{"key":"R16-5-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-002-1299-4","article-title":"Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.","volume":"166","author":"Welge","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/archpsyc.1984.01790190056007","article-title":"Identification of true drug response to antidepressants. Use of pattern analysis.","volume":"41","author":"Quitkin","year":"1984","journal-title":"Arch Gen Psychiatry"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.","volume":"69","author":"Meltzer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0269881106062765","article-title":"Selecting antipsychotics in schizophrenia: lessons from CATIE.","volume":"20","author":"Haddad","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2009.08040613","article-title":"A randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.","volume":"166","author":"Canuso","year":"2009","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200912000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:14:51Z","timestamp":1618035291000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200912000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181befa2a","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}